Riverain Technologies

What Riverain Technologies does

Riverain Technologies is a privately held medical imaging AI company founded in 2004 and headquartered in Miamisburg, Ohio. The company develops the ClearRead suite of cardiothoracic imaging software for chest CT and chest X-ray, built around its proprietary Clear Visual Intelligence (CVI) suppression technology that removes interfering structures — ribs, clavicles, blood vessels, and machine noise — to give radiologists an unobstructed view of lung tissue. The two core products, ClearRead CT and ClearRead Xray, operate as modular suites: ClearRead CT includes Vessel Suppress, Detect (nodule segmentation and volumetric measurement), Compare (prior exam comparison), and CAC scoring modules, while ClearRead Xray includes Bone Suppression, Confirm (Enhanced), and Pneumothorax detection. All ClearRead outputs are pushed back into the customer's existing PACS as additional image series, requiring no separate viewer or login.

The company sells primarily through direct enterprise sales to hospitals, health systems, academic medical centers, VA/DoD facilities, radiology groups, and outpatient imaging centers, supplemented by an extensive channel and OEM footprint spanning Siemens Healthineers (syngo.via), Aidoc, Ferrum Health, ConcertAI/TeraRecon, deepcOS, CARPL.ai marketplace, and a master services agreement with Strategic Radiology (1,500+ radiologists). Revenue is generated via SaaS subscriptions on a per-scan usage basis (~$6.00 per scan per the published CAC ROI calculator), with pricing varying by volume and configuration. The VA Lung Precision Oncology Program (LPOP) deployment across 104 VA sites is a flagship federal contract; the company reports 400+ customer locations globally, 4M+ exams processed annually, and 100% customer retention entering 2024. Customer growth has been hyper-growth-tier: 286% YoY in 2023 and 147% YoY in 2024, with 50 new customers added in 2024 and expansion into eight new countries.

Regulatory footprint includes FDA 510(k) clearances (concurrent-read CT vessel suppression), EU MDR certification (February 2022), TGA approval (Australia), Health Canada approval (March 2025 for CAC), and ISO 27001. The company is managed by CEO Steve Worrell, with a leadership team including CCO Mark Koeniguer and CPO Ofer Pinhasi. Clinical evidence includes multiple peer-reviewed studies showing 29% reduction in missed pulmonary nodules, 26–36% faster reading times, 21% greater nodule detection on vessel-suppressed CT, and improved inter-reader agreement. A new Medicare reimbursement pathway (code G0680) for AI-powered CAC scoring on routine chest CTs takes effect April 1, 2026, layering a reimbursement lever on top of the existing SaaS revenue model and significantly expanding the economic case for adoption.

Name

Riverain Technologies

Legal name

Riverain Technologies

Website

https://riveraintech.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

Riverain Technologies is a private medical imaging AI company (founded 2004, Miamisburg, Ohio) that sells the ClearRead suite of chest CT and X-ray AI tools — using proprietary vessel/bone suppression — to hospitals, VA medical centers, academic medical centers, and radiology groups globally via per-scan SaaS and OEM channels.

Ownership category

akta.pro rank

Product category

Medical Imaging AI Software

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)

akta.pro secondary industries

Vendor Neutral Archive (VNA) & Enterprise Imaging Repositories (HLACALAC), Radiology Reporting, Dictation & Structured Reporting (HLACALAF), Universal Viewers & Enterprise Imaging Access (Zero-footprint/Diagnostic) (HLACALAD)

Keywords

• Medical imaging AI
• Chest CT analysis
• Pulmonary nodule detection
• Bone suppression imaging
• Coronary artery calcium scoring

Headquarters

HQ city

Miamisburg

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Software as a Service (SaaS) Subscription: SaaS pricing model for ClearRead solutions, with per-scan costs. CAC Reimbursement ROI tool references a SaaS cost of $6.00 per scan. Pricing varies by customer volume, study type, and configuration. Revenue recognized through software licensing and subscription contracts with healthcare providers.

Pricing tiers

Go-to-market motion3 records

Distribution channels8 records

Marketing channels9 records

Core offering

Riverain Technologies develops and sells ClearRead, an FDA-cleared AI-powered chest imaging software suite (ClearRead CT for chest CT and ClearRead Xray for chest X-ray) used by radiologists to detect pulmonary nodules, coronary artery calcification, and pneumothorax. The products are built on proprietary Clear Visual Intelligence (CVI) suppression technology that removes bones, vessels, and machine noise from chest images to improve reading accuracy and reduce reading time, and integrate natively into existing PACS workflows.

Product overview

Riverain Technologies offers a unified ClearRead suite of AI-powered chest imaging interpretation solutions built around its proprietary Clear Visual Intelligence (CVI) suppression technology. The portfolio centers on two core products: ClearRead CT (a cardiothoracic AI suite for chest CT scans) and ClearRead Xray (for chest X-rays). These are available as standalone tools or within a modular architecture: ClearRead CT includes Vessel Suppress, Detect, Compare, and CAC Scoring modules; ClearRead Xray includes Bone Suppression, Confirm (Enhanced), and Pneumothorax detection modules. All products integrate directly into PACS systems as additional series within existing workflows, with no separate viewer or login required. The company operates from Miamisburg, Ohio, and serves over 400 customer locations globally with products deployed across hospitals, VA medical centers, and radiology groups.

Differentiator

Problem solved

Functional benefit

Brands

• ClearRead CT: AI-powered cardiothoracic imaging suite for pulmonary nodule detection and coronary artery calcification (CAC) scoring on chest CT scans.
• ClearRead Xray
• Clear Visual Intelligence (CVI)
• Certainty of Search (CoS)

Products and services

• ClearRead CT FDA-cleared AI-powered cardiothoracic imaging suite for chest CT scans used by radiologists to detect, segment, and measure pulmonary nodules and quantify coronary artery calcification (CAC) with Agatston scoring. Built on proprietary vessel suppression technology that removes vascular structures from chest CT images, providing an unimpaired view that improves nodule detection accuracy, supports prior exam comparison, and reduces reading time. Integrates natively into existing PACS systems as an additional image series. Targeted at hospitals, health systems, VA/DoD facilities, academic medical centers, and outpatient imaging centers.
• ClearRead Xray FDA-cleared AI-powered chest X-ray suite that uses patented bone suppression technology to remove ribs and clavicles from frontal chest radiographs, plus computer-assisted detection for pulmonary nodules and pneumothorax. Provides an unimpaired view of the chest to improve detection accuracy and reading workflow, and is device and protocol agnostic, working across all manufacturers' X-ray equipment without additional radiation dose. Integrates natively into existing PACS systems. Targeted at hospitals, health systems, VA/DoD facilities, academic medical centers, and outpatient imaging centers.

Quantifiable outcome

• 29% reduction in missed pulmonary nodules
• +9 more outcomes

Named customers27 records

Segments6 records

Ideal customer profiles6 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration11 records

AI capability3 records

Feature6 records

Partnerships

Eleven partnerships are on record, tiered strategic, minor and core.

• VIDA DiagnosticsstrategicTechnology or Integration · 30 November 2025VIDA Diagnostics integrates Riverain's AI imaging analysis suite into its clinical trial platform, announced at RSNA conference. Collaboration aims to enhance biomarker data quality and operational efficiency in global clinical trials for COPD, cardiovascular disease, and lung cancer — collectively causing 40% of global deaths. VIDA serves the life sciences and clinical research market.
• deepc (deepcOS)strategicTechnology or Integration · 18 November 2025deepcOS integrates Riverain Technologies' ClearRead solutions into its enterprise health AI operating system. The partnership enriches deepc's enterprise health AI portfolio with Riverain's clinically proven chest imaging AI, extending access to healthcare providers through the deepcOS platform.
• BialogicsminorImplementation/ SI/ Consulting Partner · 5 November 2025Bialogics and Riverain partnership sets a new benchmark for AI adoption in healthcare imaging. Bialogics provides AI adoption benchmarking and implementation support services that help healthcare organizations integrate Riverain's ClearRead solutions effectively into their imaging workflows.
• Azra AIstrategicTechnology or Integration · 1 October 2025Azra AI and Riverain Technologies collaborate to integrate advanced AI for end-to-end lung cancer detection and care coordination. Combines Riverain's ClearRead nodule detection with Azra AI's care coordination and follow-up management to create a comprehensive lung cancer detection and patient management workflow.
• CARPL.aistrategicTechnology or Integration · 18 March 2025CARPL.ai adds ClearRead CT and ClearRead Xray to its vendor-neutral AI marketplace, which now offers 160+ AI applications. Partnership expands global access to AI for lung cancer detection by making Riverain's FDA-cleared solutions available alongside other AI tools within a single platform. Enables radiologists to evaluate and implement the best AI solutions for their practice.
• RevealDxstrategicChannel Partner/ Reseller/ Distributor · 3 October 2024RevealDx and Riverain integrate their products with distribution by Riverain in Canada. RevealDx's RevealAI-Lung software uses a Malignancy Similarity Index (mSI) for patient follow-up recommendations, while Riverain's ClearRead CT provides vessel suppression, nodule detection, and volumetric data. Partnership builds on ClearRead benefits by adding malignancy characterization to improve follow-up recommendations. Riverain distributes RevealDx's technology in Canada.
• Strategic RadiologystrategicChannel Partner/ Reseller/ Distributor · 6 September 2023Master Services Agreement with Strategic Radiology, a national coalition of 35 privately owned independent radiology practices representing 1,500+ radiologists. Agreement provides Strategic Radiology member practices access to ClearRead solutions, bringing state-of-the-art AI tools to independent radiology practices to improve quality and efficiency of radiology services.
• Siemens HealthineerscoreChannel Partner/ Reseller/ Distributor · 21 March 2023Extension of long-standing partnership. ClearRead Xray Bone Suppression is available on Siemens Healthineers syngo.via OpenApps platform and Digital Marketplace, serving customers in Europe and the US. Enables Siemens Healthineers customers to browse, test, download, and request quotations for ClearRead directly through their existing infrastructure. Extension of enterprise solution supporting standard-of-care deployment.
• Ferrum HealthcoreOEM/ Whitelabel/ Licensing Partner · 14 March 2023ClearRead CT and ClearRead Xray available on Ferrum Health Private AI Hub, the nation's most widely deployed private AI platform for imaging. Partnership enables healthcare providers to access ClearRead with real-time access to the latest medical imaging technology while reducing implementation costs. Brings together two industry leaders with shared goal of accelerating AI adoption.
• ConcertAI TeraReconcoreOEM/ Whitelabel/ Licensing Partner · 1 March 2023ClearRead CT and ClearRead Xray integrated into ConcertAI's TeraRecon Eureka Clinical AI platform, providing one point of access to clinically proven AI solutions delivered in a streamlined manner into existing physician workflows. Eureka platform serves as a central hub for AI imaging solutions accessible to healthcare providers.
• AidoccoreTechnology or Integration · 5 October 2021Riverain and Aidoc partnership integrates Riverain's commercially available FDA-cleared lung nodule detection and measurement algorithms with Aidoc's platform, which serves ~600 medical centers globally. Aidoc provides its PE, incidental PE, and rib fracture modules in exchange. The combined offering delivers a unified cross-specialty AI experience with a seamless workflow, enabling radiologists to read faster while improving patient outcomes. Both companies co-market the integrated chest AI package.

Scale indicators9 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Aidoc: Aidoc is a radiology AI platform serving ~600 medical centers with cross-specialty AI modules including PE and rib fracture. Riverain and Aidoc have a formal integration partnership but also compete in adjacent chest AI workflows, making Aidoc the closest direct peer in platform-based radiology AI distribution.
• Annalise.ai: Annalise.ai is a chest X-ray AI vendor offering comprehensive CXR triage and detection across 124+ findings. Directly comparable to ClearRead Xray in clinical use case (chest X-ray AI), target customer (radiology departments), and enterprise SaaS model.
• Qure.ai: Qure.ai is a global radiology AI company with FDA-cleared chest X-ray and head CT products (qXR, qER) targeting pulmonary nodule, TB, and pneumothorax detection. Direct overlap with ClearRead Xray in chest X-ray AI and pulmonary nodule detection, serving similar hospital and emerging-market segments.
• Lunit: Lunit is a Korean publicly-listed medical AI company with Lunit INSIGHT CXR for chest X-ray anomaly detection (including nodule and pneumothorax) and Lunit INSIGHT MMG for mammography. Direct chest X-ray AI competitor with global enterprise hospital footprint comparable to ClearRead Xray's go-to-market.
• VIDA Diagnostics: VIDA Diagnostics is a lung imaging AI company focused on quantitative CT analysis for clinical trials and COPD/emphysema phenotyping. Direct peer in lung CT imaging AI, formally partnered with Riverain for clinical trial biomarker applications, serving overlapping pharmaceutical and academic medical center customers.
• RevealDx: RevealDx offers RevealAI-Lung, a malignancy probability scoring tool for lung nodules on CT that integrates with ClearRead CT. Direct peer in lung cancer screening AI, with formal partnership for combined nodule detection plus malignancy characterization workflow in Canada.

Broad incumbents

• Siemens Healthineers: Siemens Healthineers is the OEM partner distributing ClearRead through its syngo.via OpenApps and Digital Marketplace, but it is also a broad incumbent that develops its own AI Radiology Assistants and bundles imaging AI across CT, MR, and X-ray. Comparable as the dominant imaging modality vendor with overlapping chest AI offerings.
• GE HealthCare: GE HealthCare is a global imaging equipment and AI vendor offering Edison AI platform with chest imaging applications including nodule detection and lung screening. Broad incumbent comparable as integrated imaging modality + AI provider competing for similar enterprise hospital and lung screening program contracts.
• Philips (Philips HealthSuite / AI Manager): Philips operates an AI Manager platform integrating third-party and proprietary radiology AI applications across CT, MR, and X-ray. Broad incumbent comparable as large modality vendor with chest CT/X-ray AI capabilities distributed through enterprise hospital contracts overlapping Riverain's customer base.

Emerging players

• Deepc: Deepc operates the deepcOS enterprise health AI operating system and integrates third-party radiology AI including ClearRead. Comparable as a radiology AI orchestration platform and marketplace partner, with emerging overlap in chest imaging deployment to European hospital systems.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/riverain-medical
• Xx.com/RiverainTech
• Facebookfacebook.com/RiverainTechnologies

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Riverain Technologies